Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Phillips, Christine
PACT, NCT03848312: Preventing Alzheimer's With Cognitive Training	Recruiting	3	7600	US	Cognitive Training, Computerized Cognitive Stimulation	University of South Florida, National Institute on Aging (NIA)	Age-related Cognitive Decline, Alzheimer's Disease and Related Dementias	01/26	01/26
REFUEL, NCT05460533: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)	Recruiting	2	33	US	Tisagenlecleucel	Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals	B-cell Acute Lymphoblastic Leukemia	07/26	07/26
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL	Active, not recruiting	2	121	Europe, Canada, US	CTL019	Novartis Pharmaceuticals, Children's Oncology Group	B-Cell Acute Lymphoblastic Leukemia	10/27	10/27
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients	Available	N/A		Canada, US, RoW	CTL019, tisagenlecleucel, Kymriah	Novartis Pharmaceuticals	Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
Driscoll, Timothy A
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL	Active, not recruiting	2	121	Europe, Canada, US	CTL019	Novartis Pharmaceuticals, Children's Oncology Group	B-Cell Acute Lymphoblastic Leukemia	10/27	10/27
Rodden, Kelly
NCT03025087: Hydroxychloroquine and Cognitive Function After Surgery	Terminated	4	24	US	Hydroxychloroquine	Duke University	Individuals Undergoing Cardiac and General Surgery	05/23	04/24
NCT05524051: A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.	Recruiting	2	120	Europe, Canada, US, RoW	TIN816, Placebo	Novartis Pharmaceuticals	Acute Kidney Injury Following Cardiac Surgery	06/25	09/25
THRIVE, NCT05991453: Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial	Recruiting	N/A	12500	US	Anesthetic technique Propofol TIVA, Propofol TIVA, Anesthetic technique inhaled agent, Inhaled agent	Washington University School of Medicine, Patient-Centered Outcomes Research Institute, University of Michigan	Surgery-Complications, Anesthesia Complication, Anesthesia Awareness, Anesthesia, Surgery, Quality of Life, Pain, Postoperative, Anesthesia Morbidity	07/27	07/28
Kellogg, Bethany
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL	Active, not recruiting	2	121	Europe, Canada, US	CTL019	Novartis Pharmaceuticals, Children's Oncology Group	B-Cell Acute Lymphoblastic Leukemia	10/27	10/27